

*Ch*  
*Conf*  
*Sub A3*

Serial No.: 08/873,601

Filed: June 12, 1997

79. A method according to claim 58, wherein said nucleic acids contain localization signals.--

#### REMARKS

The present amendment accompanies a divisional application filed under 37 C.F.R. 1.53(d). Claims 58-79 are pending and are presented for consideration. For the Examiner's convenience a copy of the pending claims is appended hereto. The amendment contains no new matter.

Support for new claims 58-79 is found throughout the specification and in the claims as filed. In particular, the claims are supported by originally filed claims 9-20 and the specification at p.4, lines 8 and 10; p.8, lines 3-6 and 11; p. 16, lines 19-23; and p.31, line 23.

Applicants submit that the claims are now in condition for allowance and an early notification of such is solicited. Please direct any calls in connection with this application to the undersigned at (415) 781-1989.

Respectfully submitted,

FLEHR HOHBACH TEST  
ALBRITTON & HERBERT LLP

Dated: 5/16/01

*Robin M. Silva*  
\_\_\_\_\_  
Robin M. Silva  
Reg. 38,304

Four Embarcadero Center  
Suite 3400  
San Francisco, CA 94111-4187  
Telephone: (415) 781-1989

**Serial No.:** 08/873,601

**Filed:** June 12, 1997

Pending Claims:

58. A method of screening a plurality of cells, comprising:

- a) producing a plurality of cells comprising a library of nucleic acids encoding a library of exogenous scaffolds;
- b) introducing into said plurality of cells a library of nucleic acids each encoding at least a first enzyme and a second enzyme; and
- c) screening said plurality of cells for a cell comprising at least one exogenous scaffold and exhibiting an altered phenotype,  
wherein each of said scaffolds comprises at least a first binding site and a second binding site, and wherein said first enzyme binds to said first binding site and said second enzyme binds to said second binding site.

59. The method of claim 58, further comprising contacting said cells, prior to said screening, with a library of exogenous bioactive agent precursors.

60. A method according to claim 58, wherein each said scaffold comprises at least three binding sites.

61. A method according to claim 58, wherein each said scaffold comprises at least four binding sites.

62. A method according to claim 58, wherein each said scaffold comprises at least five binding sites.

63. A method according to claim 58, wherein said cells are mammalian cells.

64. A method according to claim 58, wherein said scaffolds are linear.

65. A method according to claim 58, wherein said library of nucleic acids encoding a library of exogenous scaffolds further comprises at least one targeting sequence.

66. A method according to claim 58, wherein said library of nucleic acids encoding a library of exogenous scaffolds further comprises at least one rescue sequence.

67. A method according to claim 58, wherein said library of nucleic acids encoding a library of exogenous scaffolds further comprises at least one stability sequence.

**Serial No.:** 08/873,601

**Filed:** June 12, 1997

68. A method according to claim 58, wherein said library of nucleic acids encoding at least a first enzyme and a second enzyme further comprises at least one targeting sequence.
69. A method according to claim 58, wherein said library of nucleic acids encoding at least a first enzyme and a second enzyme further comprises at least one rescue sequence.
70. A method according to claim 58, wherein said library of nucleic acids encoding at least a first enzyme and a second enzyme further comprises at least one stability sequence.
71. A method according to claim 58, wherein said introducing comprises retroviral infection.
72. A method according to claim 58, wherein said method further comprises isolating said cell exhibiting an altered phenotype.
73. A method according to claim 58 further comprising isolating said scaffold from said cell exhibiting an altered phenotype.
74. A method according to claim 58 further comprising isolating said nucleic acid encoding said scaffold from said cell exhibiting an altered phenotype.
75. A method according to claim 58 further comprising isolating said enzymes from said cell exhibiting an altered phenotype.
76. A method according to claim 58 further comprising isolating said nucleic acids encoding said enzymes from said cell exhibiting an altered phenotype.
77. A method according to claim 59, wherein said altered phenotype is due to the presence of one or more of said bioactive agent precursors.
78. A method according to claim 77 further comprising identifying said one or more bioactive agents.
79. A method according to claim 58, wherein said nucleic acids contain localization signals.